Centre du Cancer Lausanne




Home < Centre de recherche < Publications 2010 < Publications 2009

Publications 2010

	Publications 2009

Publications 2008

Publications 2007

Publications 2006

Publications 2005

Publications 2004

Publications 2003

Publications 2002

Publications 2001

Info.onco@chuv.ch

2009
1:	Alghisi G.C., Ponsonnet L., Rüegg C
		The integrin antagonist cilengitide activates alphaVbeta3, disrupts VE-cadherin localization at cell junctions and enhances permeability in endothelial cells. PloS one 4(2), e4449. [DOI] PloS one 4(2), e4449. [DOI]
2:	BIG 1-98 Collaborative Group (S. Leyvraz for the group of Lausanne)
		Design, conduct and analyses of Breast International Group (BIG) 1-98 : a randomized, double-blind, phase-III study comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with receptor-positive, early breast cancer Clin Trials 5 : 272-287, 2009
3:	BIG 1-98 Collaborative Group (S. Leyvraz for the group of Lausanne)
		Letrozole therapy alone or in sequence with Tamoxifen in women with breast cancer. N Engl J Med 361 : 766-776m 2009
4:	Baerenswyl V., Zumsteg A, Imaizumi N., R. Schwendener, Rüegg C. and G. Christofori
		Myeloid cells contribute to tumor lymphangiogenesis. PLoS ONE, Sep 17;4(9):e7067.
5:	Berthold D.
		Reply to 'Third consensus on medical treatment of metastatic breast cancer'. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO , 15. [DOI] [Pubmed]
6:	Bizzini A., Entenza J.M., Michielin O., Arnold I., Erni B., Moreillon P.
		A single mutation in enzyme I of the sugar phosphotransferase system confers penicillin tolerance to Streptococcus gordonii. Antimicrobial agents and chemotherapy 54(1), 259-66. [DOI] [Pubmed]
7:	Brandes AA, Stupp R, Hau P, Lacombe D, Gorlia T, Tosoni A, Mirimanoff RO, Kros JM, Van den Bent MJ., 2009. EORTC study 26041-22041
		Phase I/II study on concomitant and adjuvant temozolomide (TMZ) and radiotherapy (RT) with PTK787/ZK222584 (PTK/ZK) in newly diagnosed glioblastoma. European journal of cancer (Oxford, England : 1990) , 15. [DOI] [Pubmed]
8:	Brembilla N.C., Cohen-Salmon I., Weber J., Rüegg C., Quadroni M., Harshman K., Doucey M.A.
		Profiling of T-cell receptor signaling complex assembly in human CD4 T-lymphocytes using RP protein arrays. Proteomics 9(2), 299-309. [DOI] [Pubmed]
9:	Bricard G., Cesson V., Devevre E., Bouzourene H., Barbey C., Rufer N., Im J.S., Alves P.M., Martinet O., Halkic N., Cerottini J.C., Romero P., Porcelli S.A., Macdonald H.R., Speiser D.E.
		Enrichment of human CD4+ V(alpha)24/Vbeta11 invariant NKT cells in intrahepatic malignant tumors. Journal of immunology (Baltimore, Md. : 1950) 182(8), 5140-51
10:	Bulliard Y., Turelli P., Röhrig U.F., Zoete V., Mangeat B., Michielin O., Trono D.
		Functional analysis and structural modeling of human APOBEC3G reveal the role of evolutionarily conserved elements in the inhibition of human immunodeficiency virus type 1 infection and Alu transposition. Journal of virology 83(23), 12611-21.
11:	Cheng C., Haouala A., Krueger T., Mithieux F., Perentes J.Y., Peters S., Decosterd L.A., Ris H.B.
		Drug uptake in a rodent sarcoma model after intravenous injection or isolated lung perfusion of free/liposomal doxorubicin. Interactive cardiovascular and thoracic surgery 8(6), 635-8
12:	Colzani M., Waridel P., Laurent J., Faes E., Rüegg C., Quadroni M.
		Metabolic labeling and protein linearization technology allow the study of proteins secreted by cultured cells in serum-containing media. Journal of proteome research 8(10), 4779-88.
13:	Colzani, M., Bienvenut, W.V., Faes, E., Quadroni, M.
		Precursor ion scans for the targeted detection os stable-isotope-labeled peptides. Rapid Commun. Mass Spectrom. 2009 ; 23 : 3570-3578
14:	Dei Tos A.P., Wagner A.J., Modena P., Comandone A., Leyvraz S.
		Epithelioid soft tissue tumors. Seminars in oncology 36(4), 347-57.
15:	Derré L., Rivals J.P., Jandus C., Pastor S., Rimoldi D., Romero P., Michielin O., Olive D., Speiser D.E.
		BTLA mediates inhibition of human tumor-specific CD8+ T cells that can be partially reversed by vaccination. The Journal of clinical investigation 120(1), 157-67.
16:	Dirnhofer S., Leyvraz S.
		Current standards and progress in understanding and treatment of GIST. Swiss medical weekly : official journal of the Swiss Society of Infectious Diseases, the Swiss Society of Internal Medicine, the Swiss Society of Pneumology 139(7-8), 90-102
17:	Eisen T., Thatcher N., Leyvraz S., Miller W.H., Couture F., Lorigan P., Lüthi F., Small D., Tanovic A., O'Brien M.
		Phase II study of weekly plitidepsin as second-line therapy for small cell lung cancer. Lung cancer (Amsterdam, Netherlands) 64(1), 60-5.
18:	French Sarcoma Group (S. Leyvraz for the group of Lausanne)
		Neo/adjuvant chemotherapy does not improve outcome in resected primary synovial sarcoma : a study of the French Sarcoma Group Ann Oncol 20 : 425-430, 2009.
19:	Frossard V., Ketterer N., Rosselet A., Meier P., Cairoli A., Duchosal M.A., Kovacsovics T.
		Early intensification and autologous stem cell transplantation in patients with systemic AL amyloidosis: a single-centre experience. Annals of hematology 88(7), 681-5.
20:	Green R.M., Cloughesy T.F., Stupp R., DeAngelis L.M., Woyshner E.A., Ney D.E., Lassman A.B.
		Bevacizumab for recurrent ependymoma. Neurology 73(20), 1677-80.
21:	Grosdidier A., Zoete V., Michielin O.
		Blind docking of 260 protein-ligand complexes with EADock 2.0. Journal of computational chemistry 30(13), 2021-30.
22:	Guillaume P, Baumgartner P, Neff L, Rufer N, Wettstein P, Speiser DE, Luescher IF.
		Novel soluble HLA-A2/MELAN-A complexes selectively stain a differentiation defective subpopulation of CD8+ T cells in melanoma patients. International journal of cancer. Journal international du cancer , 15.
23:	Halouala A, Widmer N, Montemurro M, Buclin T, Decosterd LA.
		Cardiovascular drug interaction with tyrosine kinase inhibiotors. Kardiovascuäre Medizin 2009 ; 12 (dezember)
24:	Haouala A., Zanolari B., Rochat B., Montemurro M., Zaman K., Duchosal M.A., Ris H.B., Leyvraz S., Widmer N., Decosterd L.A.
		Therapeutic Drug Monitoring of the new targeted anticancer agents imatinib, nilotinib, dasatinib, sunitinib, sorafenib and lapatinib by LC tandem mass spectrometry. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 877(22), 1982-96.
25:	Harousseau J.L., Avet-Loiseau H., Attal M., Charbonnel C., Garban F., Hulin C., Michallet M., Facon T., Garderet L., Marit G., Ketterer N., Lamy T., Voillat L., Guilhot F., Doyen C., Mathiot C., Moreau P.
		Achievement of at least very good partial response is a simple and robust prognostic factor in patients with multiple myeloma treated with high-dose therapy: long-term analysis of the IFM 99-02 and 99-04 Trials. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 27(34), 5720-6.
26:	Hegi M.E., Sciuscio D., Murat A., Levivier M., Stupp R.
		Epigenetic deregulation of DNA repair and its potential for therapy. Clinical cancer research : an official journal of the American Association for Cancer Research 15(16), 5026-31
27:	Hornitschek P., Lorrain S., Zoete V., Michielin O., Fankhauser C.
		Inhibition of the shade avoidance response by formation of non-DNA binding bHLH heterodimers. The EMBO journal 28(24), 3893-902.
28:	Iancu E.M., Corthesy P., Baumgaertner P., Devevre E., Voelter V., Romero P., Speiser D.E., Rufer N.
		Clonotype selection and composition of human CD8 T cells specific for persistent herpes viruses varies with differentiation but is stable over time. Journal of immunology (Baltimore, Md. : 1950) 183(1), 319-31.
29:	International Breast Cancer Study Group (S. Leyvraz for the group of Lausanne)
		Second non-breast primary cancer following adjuvant therapy for early breast cancer : a report from the International Breast Cancer Study Group. Eur. J. Cancer 45 : 561-571, 2009.
30:	International Breast Cancer Study Group (S. Leyvraz for the group of Lausanne)
		The effect of endocrine responsiveness on high-risk breast cancer treated with dose-intensive chemotherapy : results of International Breast Cancer Study Group Trial 15-95 after prolonged follow-up. Ann Oncol 20 : 1344-1351, 2009.
31:	International Breast Cancer Study Group (S. Leyvraz for the group of Lausanne)
		Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial. Ann Oncol. 20 : 1489-1498, 2009.
32:	International Breast Cancer Study Group (S. Leyvraz for the group of Lausanne)
		Is adjuvant chemotherapy of benefit for postmenopausal women who receive endocrine treatment for highly endocrine-responsive, node-positive breast cancer ? International Breast Cancer Study Group Trials VII and 12-93. Breast Cancer Res Treat. 116 : 491-500, 2009.
33:	Jandus C., Bioley G., Dojcinovic D., Derré L., Baitsch L., Wieckowski S., Rufer N., Kwok W.W., Tiercy J.M., Luescher I.F., Speiser D.E., Romero P.
		Tumor antigen-specific FOXP3+ CD4 T cells identified in human metastatic melanoma: peptide vaccination results in selective expansion of Th1-like counterparts. Cancer research 69(20), 8085-93.
34:	Jichlinski P, Berthold DR, Zouhair A, Griesser AC, Meuwly JY, Prior JO, Lhermitte B, Doerfler A, Treuthardt C, Praz V, Tawadros T, Vaucher L, Aymon D, Marazzi A, Levi F, Beckmann J, Leyvraz S, Bauer J.
		Active surveillance for early-stage prostate cancer Rev Med Suisse. 2009 Dec 2;5(228):2442-4, 2446-7.
35:	Le Cesne A., Van Glabbeke M., Verweij J., Casali P.G., Findlay M., Reichardt P., Issels R., Judson I., Schoffski P., Leyvraz S., Bui B., Hogendoorn P.C., Sciot R., Blay J.Y.
		Absence of progression as assessed by response evaluation criteria in solid tumors predicts survival in advanced GI stromal tumors treated with imatinib mesylate: the intergroup EORTC-ISG-AGITG phase III trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 27(24), 3969-74
36:	Lefebvre J.L., Rolland F., Tesselaar M., Bardet E., Leemans C.R., Geoffrois L., Hupperets P., Barzan L., de Raucourt D., Chevalier D., Licitra L., Lunghi F., Stupp R., Lacombe D., Bogaerts J., Horiot J.C., Bernier J., Vermorken J.B.
		Phase 3 randomized trial on larynx preservation comparing sequential vs alternating chemotherapy and radiotherapy. Journal of the National Cancer Institute 101(3), 142-52.
37:	Martina E, Degen M, Rüegg C, Merlo A, Lino MM, Chiquet-Ehrismann R, Brellier F.
		Tenascin-W is a specific marker of glioma-associated blood vessels and stimulates angiogenesis in vitro. The FASEB journal : official publication of the Federation of American Societies for Experimental Biology , 15
38:	Marx K., Bauer J., Guillou L., Delaloye A.B., Prior J.
		Bellini duct carcinoma: visualization on F-18 FDG PET/CT. Clinical nuclear medicine 34(8), 541-2.
39:	Maurer G.D., Tritschler I., Adams B., Tabatabai G., Wick W., Stupp R., Weller M.
		Cilengitide modulates attachment and viability of human glioma cells, but not sensitivity to irradiation or temozolomide in vitro. Neuro-oncology 11(6), 747-56.
40:	Montemurro M. , Schöffski P. , Reichardt P. , Gelderblom H. , Schütte J. , Hartmann J.T. , von Moos R. , Seddon B. , Joensuu H. , Wendtner C.M. , Weber E. , Grünwald V. , Roth A. , Leyvraz S.
		Nilotinib in the treatment of advanced gastrointestinal stromal tumours resistant to both imatinib and sunitinib. European journal of cancer (Oxford, England : 1990) 45(13) p. 2293-7
41:	Mouta-Bellum C, Kirov A, Miceli-Libby L, Mancini ML, Petrova T.V., Liaw L, Prudovsky I, Thorpe PE, Miura N, Cantley LC, Alitalo K, Fruman DA, Vary CP
		Organ-specific lymphangiectasia, arrested lymphatic sprouting, and maturation defects resulting from gene-targeting of the PI3K regulatory isoforms p85alpha, p55alpha, and p50alpha Dev Dyn. 238, 2670-2679
42:	Murat A., Migliavacca E., Hussain S.F., Heimberger A.B., Desbaillets I., Hamou M.F., Rüegg C., Stupp R., Delorenzi M., Hegi M.E.
		Modulation of angiogenic and inflammatory response in glioblastoma by hypoxia. PloS one 4(6), e5947
43:	Neyns B., Hoorens A., Stupp R.
		Valproic acid related idiosyncratic drug induced hepatotoxicity in a glioblastoma patient treated with temozolomide. Acta neurologica Belgica 108(4), 131-4
44:	Norrmén, C., Ivanov, K.I., Cheng, J., Zangger, N., Delorenzi, M., Jaquet, M., Miura, N., Puolakkainen, P., Horsley, V., Hu, J., Augustin, H.G., Ylä-Herttuala, S., Alitalo, K. & Petrova, T.V.
		FOXC2 controls formation and maturation of lymphatic collecting vessels through cooperation with NFATc1 J. Cell. Biol., 185, 439-57 (journal cover and In Focus editorial article)
45:	Norrmén, C., Vandevelde, W., Ny, A., Saharinen, P., Gentile, M., Haraldsen, G., Puolakkainen, P., Lukanidin, E., Dewerchin, M., Alitalo, K.& Petrova, T.V
		Liprin ß1 is highly expressed in lymphatic vasculature and is important for lymphatic vessel integrity Blood, 115, 906-9, 2
46:	Novy J., Stupp R., Rossetti A.O.
		Pregabalin in patients with primary brain tumors and seizures: a preliminary observation. Clinical neurology and neurosurgery 111(2), 171-3.
47:	Pampallona S., Leyvraz S.
		Response “A three fold dose intensity treatment with Ifosfamide, Carboplatin, and Etoposide for patients with small-cell lung cancer : a randomized trial”. Correspondance. J Nat Cancer Inst 101 : 67-68, 2009.
48:	Peters S., Betticher D.C.
		Rôle de l'EGFR dans le cancer pulmonaire non à petites cellules [The role of EGFR in non-small cell lung carcinoma]. Revue médicale suisse 5(204), 1096-8, 1100-1.
49:	Prior J.O., Montemurro M., Orcurto M.V., Michielin O., Luthi F., Benhattar J., Guillou L., Elsig V., Stupp R., Delaloye A.B., Leyvraz S.
		Early prediction of response to sunitinib after imatinib failure by 18F-fluorodeoxyglucose positron emission tomography in patients with gastrointestinal stromal tumor. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 27(3), 439-45.
50:	Prior J.O., Stupp R., Christodoulou M., Letovanec I.
		Micropapillary pattern in lung adenocarcinoma: aspect on 18F-fluorodeoxyglucose positron emission tomography/computed tomography imaging. Interactive cardiovascular and thoracic surgery 10(1), 144-5.
51:	Röhrig U.F., Grosdidier A., Zoete V., Michielin O.
		Docking to heme proteins. Journal of computational chemistry 30(14), 2305-15.
52:	Rüegg C., Alghisi G.C.
		Vascular integrins: therapeutic and imaging targets of tumor angiogenesis. Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer 180, 83-101.
53:	Rüegg C., Peters S.
		Thalidomide in small cell lung cancer: wrong drug or wrong disease? Journal of the National Cancer Institute 101(15), 1034-5.
54:	Riklin C, Guntern D, Leyvraz S, Montemurro M.
		Badminton, rectal cancer and 25 kg weight gain during chemotherapy. Acta oncologica (Stockholm, Sweden) , 1-3.
55:	Schüpbach T., Zoete V., Tsakam-Sotché B., Michielin O.
		Fourier transform convolution integrals applied to generalized Born molecular volume. Journal of computational chemistry 31(3), 649-59
56:	Schusterbauer C., Cairoli A., Ketterer N.
		Lymphome et grossesse: quelle prise en charge [Management of lymphoma and pregnancy]. médicale suisse 5(204) p. 1104-6, 1108-9.
57:	Sekoranja L, Griesser AC, Wagner G, Njamnshi AK, Temperli P, Herrmann FR, Grandjean R, Niquille M, Vermeulen B, Rutschmann OT, Sarasin F, Sztajzel R.
		Factors influencing emergency delays in acute stroke management. Swiss Med Wkly. 2009 Jul 11;139(27-28):393-9.
58:	Shnaper S., Desbaillets I., Brown D.A., Murat A., Migliavacca E., Schluep M., Ostermann S., Hamou M.F., Stupp R., Breit S.N., de Tribolet N., Hegi M.E.
		Elevated levels of MIC-1/GDF15 in the cerebrospinal fluid of patients are associated with glioblastoma and worse outcome. International journal of cancer. Journal international du cancer 125(11), 2624-30.
59:	Stupp R., Hegi M.E., Mason W.P., van den Bent M.J., Taphoorn M.J., Janzer R.C., Ludwin S.K., Allgeier A., Fisher B., Belanger K., Hau P., Brandes A.A., Gijtenbeek J., Marosi C., Vecht C.J., Mokhtari K., Wesseling P., Villa S., Eisenhauer E., Gorlia T., Weller M., Lacombe D., Cairncross J.G., Mirimanoff R.O.
		Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. The lancet oncology 10(5), 459-66
60:	Stupp R., Mayer M., Kann R., Weder W., Zouhair A., Betticher D.C., Roth A.D., Stahel R.A., Majno S.B., Peters S., Jost L., Furrer M., Thierstein S., Schmid R.A., Hsu-Schmitz S.F., Mirimanoff R.O., Ris H.B., Pless M.
		Neoadjuvant chemotherapy and radiotherapy followed by surgery in selected patients with stage IIIB non-small-cell lung cancer: a multicentre phase II trial. The lancet oncology 10(8), 785-93.
61:	Stupp R., Roila F.
		Malignant glioma: ESMO clinical recommendations for diagnosis, treatment and follow-up Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 20 Suppl 4, 126-8.
62:	Tawadros T, Doerfler A, Treuthardt T, Praz V, Levi F, Zouhair A, Berthold D.R., Bauer J., Iselin C, Jichlinski P
		Dépistage du cancer de la prostate actualité. Rev Med Suisse. 2009 Dec 2;5(228):2438-41
63:	Thiel, A.,Ganesan, A., Mrena, J., Junnila, J., Nykänen, A.,Hemmes, A., Tai,H.H., Monni, O., Kokkola, A., Haglund, C., Petrova, T.V., & Ristimäki, A.
		15-Hydroxyprostaglandin Dehydrogenase Is Down-regulated in Gastric Cancer Clin. Cancer Res., 15, 4572-80
64:	Touvrey C., Derré L., Devevre E., Corthesy P., Romero P., Rufer N., Speiser D.E.
		Dominant human CD8 T cell clonotypes persist simultaneously as memory and effector cells in memory phase Journal of immunology (Baltimore, Md. : 1950) 182(11), 6718-26.
65:	Trojan A., Montemurro M., Kamel M., Kristiansen G.
		Successful PDGFR-{alpha}/{beta} targeting with imatinib in uterine sarcoma Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 20(11), 1898-9.
66:	Uyl-de Groot C.A., Stupp R., van der Bent M.
		Cost-effectiveness of temozolomide for the treatment of newly diagnosed glioblastoma multiforme. Expert review of pharmacoeconomics & outcomes research 9(3), 235-41.
67:	Wagner A.D. , Buechner-Steudel P. , Moehler M. , Schmalenberg H. , Behrens R. , Fahlke J. , Wein A. , Behl S. , Kuss O. , Kleber G. , Fleig W.E.
		Gemcitabine, oxaliplatin and 5-FU in advanced bile duct and gallbladder carcinoma: two parallel, multicentre phase-II trials. British journal of cancer 101(11) p. 1846-52
68:	Wagner A.D. , Moehler M.
		Development of targeted therapies in advanced gastric cancer: promising exploratory steps in a new era. Current opinion in oncology 21(4) p. 381-5.
69:	Wagner A.D., Arnold D., Grothey A.A., Haerting J., Unverzagt S.
		Anti-angiogenic therapies for metastatic colorectal cancer. Cochrane database of systematic reviews 3, CD005392.
70:	Wagner A.D., Wedding U.
		Advances in the pharmacological treatment of gastro-oesophageal cancer. Drugs & aging 26(8) p. 627-46.
71:	Weller M, Stupp R, Reifenberger G, Brandes AA, Van der Bent MJ, Wick W, Hegi ME.
		MGMT promoter methylation in malignant gliomas: ready for personalized medicine? Nature reviews. Neurology , 1
72:	Weller M, Stupp R.
		Approval of new drugs for glioblastoma. Current opinion in neurology , 4.
73:	Weller M., Reardon D., Nabors B., Stupp R.
		Will integrin inhibitors have proangiogenic effects in the clinic? Nature medicine 15(7), 726; author reply 727
74:	Wieckowski S., Baumgaertner P., Corthesy P., Voelter V., Romero P., Speiser D.E., Rufer N.
		Fine structural variations of alphabetaTCRs selected by vaccination with natural versus altered self-antigen in melanoma patients. Journal of immunology (Baltimore, Md. : 1950) 183(8), 5397-5406.
75:	Zoete V. , Grosdidier A. , Michielin O.
		Docking, virtual high throughput screening and in silico fragment-based drug design. Journal of cellular and molecular medicine 13(2) p. 238-48.
76:	Zumsteg A., Baeriswyl V., Imaizumi N., Schwendener R., Rüegg C., Christofori G.
		Myeloid cells contribute to tumor lymphangiogenesis PloS one 4(9), e7067

Dernière modification le 05.08.2011